Pediatric Schizophrenia, Bipolar Disorder & Autism
An open-label trial assessing the safety and tolerability of the investigational study medication.
- Schizophrenia: ages 13–17, confirmed by K-SADS-PL at screening
- Bipolar disorder: ages 10–17 who have completed a qualifying prior study
- ASD: patients continuing from a qualifying prior study
- ASD enrollment currently open to ages 10–17